Vaccine Development

Patch Technology Awaits FDA Approval for Clinical Trials

Published in Vaccine Weekly, November 8th, 2000

In five to 10 years, flu vaccinations could be as simple as applying an adhesive patch.

University of Alabama, Birmingham, researcher De-chu Tang, PhD, is awaiting U.S. Food and Drug Administration approval for human trials of influenza and tetanus vaccines. The vaccine would be swabbed on the skin and covered temporarily with an adhesive patch. Eventually, the vaccine could be incorporated into the patch.

Tang invented the skin-targeted vaccine patch technology and demonstrated that it is a "remote control" for creating an immune reaction in skin cells.

"A biological army in the skin is constantly mobilized to ward off...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-11-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry